Switch theme
Sign up to access all valuation multiples
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
2016
98
LTM Revenue $8.5M
LTM EBITDA n/a
-$53.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Barinthus Biotherapeutics has a last 12-month revenue of $8.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Barinthus Biotherapeutics achieved revenue of $0.8M and an EBITDA of -$71.1M.
Barinthus Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Barinthus Biotherapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $44.7M | $0.8M | $10.0M | $8.5M | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | $5.2M | -$71.1M | n/a | n/a | XXX |
| EBITDA Margin | 12% | -8861% | NaN% | 0% | XXX |
| Net Profit | -$50.9M | $5.3M | -$73.3M | XXX | XXX |
| Net Margin | -114% | 666% | -735% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Barinthus Biotherapeutics's stock price is $1.
Barinthus Biotherapeutics has current market cap of $40.2M, and EV of -$53.2M.
See Barinthus Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$53.2M | $40.2M | XXX | XXX | XXX | XXX | $-1.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Barinthus Biotherapeutics has market cap of $40.2M and EV of -$53.2M.
Barinthus Biotherapeutics's trades at -6.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Barinthus Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Barinthus Biotherapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$53.2M | XXX | XXX | XXX |
| EV/Revenue | -5.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBarinthus Biotherapeutics's NTM/LTM revenue growth is -100%
Barinthus Biotherapeutics's revenue per employee for the last fiscal year averaged $8K, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Barinthus Biotherapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Barinthus Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Barinthus Biotherapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1144% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $8K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4968% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5164% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 10132% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Barinthus Biotherapeutics acquired XXX companies to date.
Last acquisition by Barinthus Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Barinthus Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Barinthus Biotherapeutics founded? | Barinthus Biotherapeutics was founded in 2016. |
| Where is Barinthus Biotherapeutics headquartered? | Barinthus Biotherapeutics is headquartered in United States of America. |
| How many employees does Barinthus Biotherapeutics have? | As of today, Barinthus Biotherapeutics has 98 employees. |
| Who is the CEO of Barinthus Biotherapeutics? | Barinthus Biotherapeutics's CEO is Mr. William J. Enright. |
| Is Barinthus Biotherapeutics publicy listed? | Yes, Barinthus Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Barinthus Biotherapeutics? | Barinthus Biotherapeutics trades under BRNS ticker. |
| When did Barinthus Biotherapeutics go public? | Barinthus Biotherapeutics went public in 2021. |
| Who are competitors of Barinthus Biotherapeutics? | Similar companies to Barinthus Biotherapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Barinthus Biotherapeutics? | Barinthus Biotherapeutics's current market cap is $40.2M |
| What is the current revenue of Barinthus Biotherapeutics? | Barinthus Biotherapeutics's last 12-month revenue is $8.5M. |
| What is the current EV/Revenue multiple of Barinthus Biotherapeutics? | Current revenue multiple of Barinthus Biotherapeutics is -6.3x. |
| What is the current revenue growth of Barinthus Biotherapeutics? | Barinthus Biotherapeutics revenue growth between 2023 and 2024 was 1144%. |
| Is Barinthus Biotherapeutics profitable? | Yes, Barinthus Biotherapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
